Biotechnology – Page 3

Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies

6 months ago talkbio0Tagged Biotechnology, Immunotherapy, Inflammation, multi-specific antibodies, Neoplasms, Numab, Series C

Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology

Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review

6 months ago talkbio0Tagged Astellas, Autologous (qualifier value), Biotechnology, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Lymphoma, Pipeline Review

Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology

Velia Therapeutics Closes Operations, Remains Committed to Microprotein Therapeutic Potential

6 months ago talkbio0Tagged Biotechnology, company closure, microproteins, Velia

Velia Therapeutics, microproteins, biotechnology, therapeutic potential, company closure

Revance Therapeutics Faces Competing Buyout Offers: Teoxane SA Outbids Crown Laboratories

6 months ago talkbio0Tagged Biotechnology, Crown Laboratories, Industry, Revance, sulfanilamide, Teoxane

Revance Therapeutics, Teoxane SA, Crown Laboratories, buyout offers, merger agreement, biotechnology, skincare industry

Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook

7 months ago talkbio0Tagged 2024, Biopharmaceutical manufacturing, Biosimilars, Biotechnology, Cells, Drug Discovery, gene therapy, innovations, Precision Medicine, trends qualifier

Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.

KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313

7 months ago talkbio0Tagged Bio, Biotechnology, Drug Development, KdT, NGM, NGM313, Phase 2 trial, Ventures

KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial

Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema

7 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Biotechnology, Clinical Development, Cornea, Corneal endothelial dysfunction, Edema, Phase 2 Clinical Trials, Vision

Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

7 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology